pharma · Sleep Apnea, Obstructive
Ignis Therapeutics (Suzhou)
Ignis Therapeutics (Suzhou) Limited
Ignis Therapeutics (Suzhou) is a pharma organization headquartered in CN. Primary therapeutic focus areas include Sleep Apnea, Obstructive. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent reco
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Solriamfetol
Phase 3 · small molecule · Sleep Apnea, Obstructive
Solriamfetol for Sleep Apnea, Obstructive is a Phase 3 program (small_molecule) at Ignis Therapeutics (Suzhou) Limited with 1 ClinicalTrials.gov record(s).
Internal code IGN-B0301-03
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Ignis Therapeutics (Suzhou) Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Sleep Apnea, Obstructive
- Status
- completed
- Trials
- 1